NCT03511378 2021-06-15
Immunogenicity Assessment of Peg-filgrastim vs. Neulasta® as Adjunct to Chemotherapy in Patients With Breast Cancer
Lupin Ltd.
Phase 4 Completed
Clinical Trials
8 trialsNCT02782845 2016-11-21
An Expanded Access Program of Pegfilgrastim (Neulastim) in Participants With Non-Hodgkin's Lymphoma (NHL)
Hoffmann-La Roche
Phase 4 Completed
NCT02805153 2016-06-20
PEG-rhG-CSF in Patients With Breast Cancer Receiving Chemotherapy
CSPC Baike (Shandong) Biopharmaceutical Co., Ltd.
Phase 4 Completed
NCT02805205 2016-06-20
PEG-rhG-CSF in Patients With Breast Cancer Receiving Chemotherapy to Prevent Neutropenia
CSPC Baike (Shandong) Biopharmaceutical Co., Ltd.
Phase 4 Completed
NCT02805218 2016-06-20
PEG-rhG-CSF in Patients With Lymphoma Receiving Chemotherapy
CSPC Baike (Shandong) Biopharmaceutical Co., Ltd.
Phase 4 Completed
NCT02805166 2016-06-17
PEG-rhG-CSF in Patients With Malignant Solid Tumors Receiving Chemotherapy
CSPC Baike (Shandong) Biopharmaceutical Co., Ltd.
Phase 4 Completed
NCT00277160 2010-10-08
A Study of Primary Prophylaxis With Neulasta (Pegfilgrastim) Versus Secondary Prophylaxis After Chemotherapy in Elderly Subjects (>/= 65 Years Old) With Cancer
Amgen
Phase 4 Completed
NCT00115206 2009-04-06
Neulasta® in Subjects With Advanced Non-Small-Cell Lung Cancer (NSCLC) During Chemotherapy
Amgen
Phase 4 Completed